Joint Clinical Trials Office
A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2024
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk TIA (LIBREXIA-STROKE)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 17, 2024
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 17, 2024
Phase II Study of Suratadenoturev (OBP-301) in Combination with Pembrolizumab in Immunotherapy Refractory Esophagogastric Adenocarcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 2, 2024
Targeting CD38 with Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 2, 2024
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 2, 2024
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination with Abiraterone in Patients with Metastatic Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 2, 2024
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 29, 2024
A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 15, 2024
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 15, 2024